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ABSTRACT
Following a multivariant analysis we demonstrated that children and adolescents
with Burkitt lymphoma (BL) and a 13q14.3 deletion have a significant decrease in
event free survival (EFS) despite identical short intensive multi-agent chemotherapy.
However, how this deletion in the 13q14.3 region is associated with a significant
decrease in EFS in children and adolescents with BL is largely unknown. The gene
Deleted in Lymphocytic Leukemia 1 (DLEU1) is located in the region of 13q14.3. Here,
we report that DLEU1 expression is implicated in the regulation of BL programmed cell
death, cell proliferation, and expression of apoptotic genes in transcription activatorlike effector nuclease (TALEN)s-induced DLEU1 knockdown and DLEU1 overexpressing
BL cell lines. Furthermore, NSG mice xenografted with DLEU1 knockdown BL cells had
significantly shortened survival (p < 0.05 and p < 0.005), whereas those xenografted
with DLEU1 overexpressing BL cells had significantly improved survival (p < 0.05 and
p < 0.0001), following treatment with rituximab and/or cyclophosphamide. These
data suggest that DLEU1 may in part function as a tumor suppressor gene and confer
chemoimmunotherapy resistance in children and adolescents with BL.

INTRODUCTION

American British) chemotherapy regimen in children and
adolescents with intermediate-risk and advanced BL [5,
6]. Immunotherapy, by targeting CD20 by rituximab, has
been demonstrated to alter a variety of signal transduction
pathways, including NF-κB, MAPK/ERK, JAK/STAT,
PI3K/AKT, and B-cell receptor pathways. These alterations
lead to cell death and/or sensitization of cells to the effects
of cytotoxic chemotherapeutic agents [7–9]. Furthermore,
children and adolescents with BL who relapse or progress
after initial chemoimmunotherapy have a dismal prognosis,
suggesting the development of chemoimmunotherapy
resistant disease [1, 2]. Novel strategies will be required
for the reduction of both acute morbidities and prolonged

Pediatric Burkitt lymphoma (BL) is the most
common histological subtype of non-Hodgkin lymphoma
(NHL) in children and adolescents [1, 2]. We and others
have demonstrated that the prognosis of pediatric BL has
remarkably improved over the past 40 years following the
introduction of short intensive multi-agent chemotherapy
[1–4]. However, this successful approach is limited
by significant chemotherapy-induced acute toxicity,
suggesting the need to identify less toxic and more targeted
therapy [1, 2]. We investigated the addition of the antiCD20 monoclonal antibody, rituximab, to the FAB (French
www.impactjournals.com/oncotarget
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hospital stays secondary to intensive multi-agent
chemotherapy in newly diagnosed patients with BL and/
or circumvention of chemoimmunotherapy resistance in
patients with relapsed/refractory disease.
We have previously identified secondary
chromosomal aberrations in 70% of pediatric BL patients
with a C-MYC gene rearrangement [10]. Specifically, we
identified a significantly inferior event free and overall
survival (EFS and OS) in children and adolescents with a
specific loss of the 13q14.3 locus [10, 11]. In multivariate
analysis controlling for stage, lactate dehydrogenase
(LDH) levels, country of treatment, and group
classification, children and adolescents with BL who had
a 13q deletion had significantly poorer EFS compared to
patients treated with the same French American British
(FAB) chemotherapy regimen [10].
We compared the molecular signature and gene
expression profile of pediatric BL patients treated within the
Children’s Oncology Group, National Cancer Institute, and
Berlin-Frankfurt-Munster (BFM) - pediatric NHL Group
[12] and found consistency in the pediatric BL molecular
signature [12–15]. Interestingly, Dave et al. suggested
that DLEU1 gene located at chromosome 13q14.3 region
[16, 17] is significantly amplified in adult BL vs. diffuse
large B-cell lymphoma (DLBCL), and is one of the BL
molecular classifying genes and a target of the oncogene,
C-MYC [14]. Deletion of DLEU1, therefore, may in part
form the molecular basis for the significantly inferior EFS
in children with BL and a concomitant 13q14.3 deletion
when treated with FAB chemotherapy [10].
DLEU1 has been found frequently deleted and
a potential tumor suppressor gene in hematopoietic
tumors including chronic lymphocytic leukemia (CLL)
and mantle cell lymphoma [16, 17]. An open reading
frame corresponding to a 78 amino acids sequence has
been identified in DLEU1 gene by human transcriptome,
functional genomics and proteomic analysis [18, 19]. DLEU1
protein has been predicted to interact with several cancerrelated proteins, including c-Myc, Tubulin beta-2C chain
(TUBB2C), E3 ubiquitin-protein ligase (UBR1), cellular
tumor antigen p53, and Ras association (RalGDS/AF-6)
domain family member 1 (RASSF1) [18]. Interestingly,
TUBB2C and RASSF1 are frequently silenced in human
cancers and enhance apoptosis and tumor suppression [20,
21]. UBR1 affects the cell cycle via PI3K-AKT signaling
and loss of UBR1 accelerates B-cell lymphomagenesis [22].
We have observed that the expression levels of RASSF1,
TUBB2C and UBR1 were significantly higher in BL
compared to DLBCL cell lines [23]. These data, taken
together, suggest that DLEU1 may function as a tumor
suppressor in c-Myc activated BL by repressing cell cycle
progression and enhancing programmed cell death via
protein-protein interaction. In the current study, we set out
to investigate the hypothesis that the deletion of DLEU1 in
BL may affect the expression of DLEU1 network genes and
alter signal transduction pathways leading to the inhibition
www.impactjournals.com/oncotarget

of programmed cell death and in part be responsible for
the mechanism of resistance to chemoimmunotherapy in
patients with BL with a 13q14.3 deletion.

RESULTS
Generation of TALEN mediated DLEU1
knockdown BL cell line
Three pairs of TALENs (TALEN1, TALEN2, and
TALEN3) targeting the endogenous DLEU1 gene were
constructed based on modified restriction enzyme and
ligation (REAL) assembly methods for DLEU1 gene
modification (Figure 1A). To excise the entire DLEU1
locus, TALEN1 and TALEN3 (T13), and TALEN2 and
TALEN3 (T23) were transfected into Raji cells. Single
DLEU1 knockdown Raji cell clones were screened for the
desired 23 Kb deletion which was confirmed by PCR and
sequencing analysis (Figure 1B). To ensure the purity of
a single clone, one of the positive single clones (T13-2)
was re-plated and its daughter cells, four clones T13-2-2,
T13-2-4, T13-2-14 and T13-2-16 were re-screened as
above. Quantitative RT-PCR showed significant reduction
in expression of DLEU1 compared to WT, with reductions
of 75% (p < 0.01), 80% (p < 0.05), 83% (p < 0.01), and
77% (p < 0.01) in clones T13-2-2, T13-2-4, T13-2-14, and
T13-2-16, respectively (Figure 1C). Since clone T13-2-14,
hereafter referred to as “DLEU1 knockdown (DLEU1-KD)”,
showed the highest reduction of DLEU1 mRNA, we used
this clone for all further experimentation in this study. The
DLEU1-KD clones had no significant reduction in DLEU2
mRNA (data not shown).

Establishment of DLEU1 stably overexpressing
BL cell line
DLEU1 full-length cDNA was cloned into
pEGFP-N3 expression vector and GFP-DLEU1 plasmid
was transfected into HEK293 cells to confirm expression
of the fusion protein under the fluorescent microscope
(Figure 1D and 1E). GFP-DLEU1 construct was then
stably transfected into Raji cells. The expression of
DLEU1 at mRNA level was detected by RT-PCR
(Figure 1F), and the predicted size of the fusion protein
(approximately 36 kDa) was confirmed by western
blotting analysis (Figure 1G) whereas endogenous DLEU1
protein was not detectable in GFP control.

DLEU1 expression levels have significant effects
on BL cell proliferation and programmed cell
death
To examine whether DLEU1 gene affects cell
proliferation and programmed cell death in BL, Raji
cells with or without DLEU1 knocked out (DLEU1-KD
or WT), were plated into 48-well plates and evaluated
27840
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Figure 1: TALENs-induced DLEU1 knockdown and DLEU1 stably overexpressing Raji cell line. (A) A diagram showing

the targeting of the DLEU1 locus by three different TALENs and TALE repeat arrays are shown with the repeat-variable di-residue (RVD)
underlined and represented by small colored rectangles boxes. Two monomeric TALENs (L and R) are required to bind the DLEU1 target
site to cleave DNA by fused FokI. TSS, transcription start site. (B) Single clones with TALEN1 and 3-induced DLEU1 locus disruption
(22,843bp deletion, boxed with red dot line) were isolated. (C) Comparison of expression of DLEU1 mRNA between WT control (WT)
and DLEU1 knockdown single clones T13-2-2, T13-2-4, T13-2-14 and T13-2-16 by qRT-PCR. Data are presented as mean ± SD (n = 3,
paired t test) and p-value are displayed on plot. (D) Diagram of DLEU1 gene and ORF (78 a.a). Empty GFP vector (GFP) and GFP fused
DLEU1 (GFP-DLEU1) constructs are shown. ATG, start codon; TAG, stop codon. (E) GFP and GFP-DLEU1 fusion plasmids were stably
transfected into Raji cells, and then western blotting (F) and qRT-PCR (G) were performed. Data are presented mean ± SD of triplicates
(paired t test). *p < 0.005.
www.impactjournals.com/oncotarget
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every 24 hours for cell proliferation by MTS assay
and programmed cell death by Caspase 3/7 assay.
DLEU1-KD cells showed a significant increase in cell
proliferation (20% at 24 hrs, p < 0.05; 25% at 48 hrs,
p < 0.05) (Figure 2A), and a significant reduction in
caspase 3/7 activity (25% at 24 hrs, p < 0.01; 33% at
48 hrs, p < 0.05) (Figure 2B), when compared to those
of WT cells. Conversely, when we overexpressed GFP or
GFP-DLEU1 in Raji cells, GFP-DLEU1 cells showed a
significant decrease in cell proliferation (15% reduction,
p < 0.03; 19% reduction, p < 0.03; and 15% reduction,
p < 0.01 at 24, 48 and 72 hours, respectively) (Figure 2C)
and a significant increase in programmed cell death
(10.2% increase, p < 0.02; 9.7% increase, p < 0.05 at
24 and 48 hours, respectively) (Figure 2D) compared to
GFP control cells. We further analyzed the expression of
anti- and pro-apoptotic genes in these cells, and found that
DLEU1 knockdown resulted in a significant increase in
expression of the anti-apoptotic genes (Bcl-2, Bcl-xL and
Mcl-1 ), and decrease in that of the pro-apoptotic gene
(Bax) at mRNA level (Figure 2E). Consistently, GFPDLEU1 expression induced a significant decrease in Mcl-1
and increase in Bax expression (Figure 2F). We observed
similar changes in the expression of these genes at protein
levels (Figure 2G and 2H).

KD cells treated with RTX alone (15% reduction,
p < 0.05), CTX alone (24% reduction, p < 0.05) and in
combination (35% reduction, p < 0.05) compared to
WT cells (Figure 4A). Conversely, a significant increase
in cell proliferation was observed in DLEU1-KD cells
treated with RTX alone (10% increase, p < 0.05), CTX
alone (9.4% increase, p < 0.05) and in combination
(7.7% increase, p < 0.05) (Figure 4B). Moreover, RTX
treated DLEU1-KD cells showed a significant increase
in expression of anti-apoptotic genes, Bcl-2 and Bcl-xL
(>1.3-fold, p < 0.05 and >2.0-fold, p < 0.05, respectively),
and a significant decrease in expression of the proapoptotic gene, Bax (~25%, p < 0.05) (Figure 4C). These
results were further confirmed at protein level by western
blotting analyses. (Figure 4D).

Global gene expression profiling in DLEU1
knockdown cells
To understand and elucidate the function and
mechanism of DLEU1 gene in BL, we took a genomic
approach employing Affymetrix GeneChip technology in
DLEU1-KD vs. WT cells. A total of 2,501 differentially
expressed genes (DEGs) from 21,381 human genes
were identified (>2-fold, p < 0.05, 11.7%) between
TALENs-induced DLEU1-KD cells compared to WT
cells (Figure 5A). From among the 2,501 filtered genes,
1,995 genes (1,722 known genes plus 273 unknown
genes, 79.8%) were up-regulated and 506 genes (415
known genes plus 91 unknown genes, 20.2%) were
down-regulated (Figure 5B). When DEG-associated gene
ontology (GO) terms were assessed, 126, 26 and 29 GO
terms were associated with up-regulated genes whereas
78, 15 and 27 GO terms were associated with downregulated genes (p < 0.05) among biological process,
cellular component, and molecular function categories,
respectively (Figure 5C and Supplementary Table 1).
Functional clustering results of up-regulated genes suggest
that genes related to anti-inflammatory response and antiapoptotic response were activated including STAT1, IRAK1,
ATK1, IκBα, CCNG2 and Bcl-2. Functional clustering
results of down-regulated genes suggest that chromatin
remodeling associated processes were inhibited. Notably,
hematopoietic processes, especially B cell activation or
possibly lymphoid lineage, were inhibited due to downregulation of cell adhesion. A selected subset of DLEU1
target genes with biological function were validated by real
time qRT-PCR. The results indicated a pattern consistent
with gene expression profiling data (Figure 5D).

DLEU1 significantly affects the expression of
network genes and signaling pathways in BL
To monitor the expression of DLEU1 network
genes, TUBB2C and UBR1, in DLEU1-KD cells compared
to WT, quantitative reverse-transcriptase PCR (qRT-PCR)
was performed. There was significantly reduced
expression of TUBB2C and UBR1 mRNA (60%, p < 0.05;
25%, p < 0.01, respectively) (Figure 3A) in DLEU1-KD
compared to WT cells. Furthermore, we compared protein
activation related to Akt and NF-κB signaling pathways in
DLEU1-KD and WT cells. DLEU1 knockdown resulted
in significant increase in phosphorylation level of IκBα
(2.6 fold, p < 0.01) and Akt (1.5 fold, p < 0.05) (Figure 3B
and 3C). Conversely, GFP-DLEU1 expression induced
significant inhibition of phosphorylation of IκBα (30%
reduction, p < 0.05) and Akt (46% reduction, p < 0.05)
(Figure 3D and 3E).

DLEU1 knockdown results in significant
inhibition of programmed cell death, and
increase in cell proliferation, in rituximab
and/or cyclophosphamide treated cells

Effect of DLEU1 on sensitivity of xenograft
tumors to RTX and/or CTX in vivo

We next examined the changes in cell proliferation
and caspase 3/7 dependent apoptosis in DLEU1-KD cells.
These cells were treated with rituximab (RTX) (10 ug/ml)
and cyclophosphamide (CTX) (10 mM), alone or in
combination, for 48 hours. A significant reduction was
noted in caspase 3/7-dependent apoptosis in DLEU1www.impactjournals.com/oncotarget

We further investigated whether DLEU1
expression level has any effect on the sensitivity to
RTX and/or CTX treatment of xenografted NSG mice.
27842
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DLEU1-KD or WT Raji cells engineered to express
luciferase were injected into NSG mice. Xenografted
mice were then treated with RTX (30 mg/kg), CTX
(25 mg/kg), or RTX together with CTX, weekly for
4 weeks. Mice receiving PBS served as a vehicle
control. We found that tumors formed by DLEU1-KD

cells grew faster than those by WT cells under the
treatment of RTX, CTX, or combined (Supplementary
Figure 2), indicating that the DLEU1 knockdown cells
were more resistant to the treatment of these drugs.
Consistently, we found that DLEU1-KD cells injected
mice had significantly shortened survival time compared

Figure 2: DLEU1 downregulates cell proliferation and upregulates caspase-dependent apoptosis. (A, C) Comparison of

DLEU1-KD vs WT (A) and GFP-DLEU1 vs GFP (C) cell proliferation. (B, D) Caspase 3/7 activity in DLEU1-KD vs WT cells (B) and
GFP-DLEU1 vs GFP cells (D). (E–H) mRNA (E, F) and protein (G, H) expression of anti-apoptotic and pro-apoptotic genes in the Bcl-2
family in DLEU1-KD vs WT (E, G) and GFP-DLEU1 vs GFP (F, H) cells. Data are represented as the mean ± SD of triplicates (paired
t test). *p < 0.05; **p < 0.01.
www.impactjournals.com/oncotarget
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Figure 3: DLEU1 regulates the expression of network genes and signaling pathways. (A) mRNA expression of DLEU1

network genes in DLEU1-KD vs WT cells. (B, C) Significant increase in p-Akt and p-IκBα levels in DLEU1-KD vs WT cells. (D, E)
Significant decrease in p-Akt and p-IκBα levels in GFP-DLEU1 vs GFP cells. Data are represented as the mean ± SD of triplicates (paired
t test). *p < 0.05; **p < 0.01.
www.impactjournals.com/oncotarget
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to those injected with WT cells when treated with RTX
(42 days vs. 52 days, p < 0.005), or RTX combined with
CTX (48 days vs 55.5 days, p < 0.05) (Figure 6A–6D).
In the GFP-DLEU1 overexpressed xenograft model, we

found that GFP-DLEU1 mice had significantly extended
survival compared to GFP mice following treatment of
RTX (57.5 days vs 51 days, p < 0.05, n = 8 per group),
CTX (50.5 days vs 37.5 days, p < 0.0001, n = 12 per

Figure 4: Caspase-dependent apoptosis and cell proliferation in rituximab and cyclophosphamide alone or in
combination-treated DLEU1-KD vs WT cells. (A) Caspase 3/7 activity of rituximab (RTX, 10 ug/ml), cyclophosphamide (CTX,

10 mM) and RTX plus CTX combination (RTX/CTX) treated DLEU1-KD vs WT cells. (B) Cell proliferation of RTX, CTX and RTX/CTX
treated DLEU1-KD vs WT cells. (C, D) The mRNA (C) and protein (D) expression of anti-apoptotic genes in RTX treated DLEU1-KD vs
WT cells. Data are represented as the mean ± SD of triplicates (paired t test). *p < 0.05.
www.impactjournals.com/oncotarget
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group), and RTX/CTX-combination treatment (60.5 days
vs 53 days, p < 0.05, n = 12 per group) (Figure 6E–6H and
Supplementary Figure 3).

alters 1) BL programmed cell death, cell proliferation and
the expression of DLEU1 network genes in vitro and 2)
the survival of DLEU1 knockdown and overexpressing BL
xenografted mice following chemoimmunotherapy.
We generated TALENs-mediated DLEU1 KD
(83% reduction, p < 0.01) as well as GFP-DLEU1 stable
expressing Raji BL cell lines. We investigated the effect of
DLEU1 expression on cell proliferation and programmed
cell death, and analyzed the expression of network genes
and signaling pathways in BL following treatment with
RTX and/or CTX using qRT-PCR and western blotting
analyses. Gene expression profiling was performed using
Affymetrix microarrays in DLEU1 KD BL cells compared

DISCUSSION
Children and adolescents with 13q14.3 deletion have
a significant poorer EFS compared to pediatric BL patients
without this abnormality [10, 11]. Furthermore, this region
has been determined to be the most frequently genetically
altered locus in B-CLL [24, 25] and a major control
locus of B-cell proliferation in CLL [24]. In the current
preclinical study, we investigated if DLEU1 expression

Figure 5: Gene expression patterns in DLEU1-KD vs WT. (A) Hierarchical clustering comparing the gene expression patterns

between DLEU1-KD and WT cells. Green represents decreased expression and red increased expression, according to the scale.
(B) Number of up- (left column) and down- (right column) regulated genes by DLEU1. (C) The numbers of genes in each functional
category are demonstrated. (D) Verification of DLEU1 regulated genes identified by Affymetrix Genechip profiling by qRT-PCR. GAPDH
was used as an endogenous control for normalization.
www.impactjournals.com/oncotarget

27846

Oncotarget

Figure 6: Survival of DLEU1-KD and GFP-DLEU1 mice treated with rituximab, cyclophosphamide and rituximab/
cyclophosphamide combination. (A–D) Pair-wise comparison of survival curves of WT and DLEU1-KD mice (A–D) following the
treatment of RTX, CTX, or RTX/CTX. *p < 0.05; **p < 0.005. (E–H) Pair-wise comparison of control (GFP) and DLEU1 overexpressed
(GFP-DLEU1) xenograft mice (E–H) following the treatment of RTX, CTX, or RTX/CTX. ns, not significant; *p < 0.05; **p < 0.005;
***p < 0.0001.
www.impactjournals.com/oncotarget
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to control to identify cellular processes regulated by
DLEU1. We found that DLEU1 in part regulates BL
apoptosis, cell proliferation and associated signaling
pathways. Gene expression data additionally support the
hypothesis that DLEU1 plays in part a role in BL cell
signaling by demonstrating that anti-inflammatory and
anti-apoptotic response genes, STAT1, IRAK1, ATK1, IκBα,
CCNG2 and Bcl-2 were activated whereas hematopoieticassociated and chromatin remodeling-associated genes
were downregulated in DLEU1-KD BL in comparison
to wild type BL cells. These observations are consistent
with the recent report of tumor suppressive function within
the genetic region of 13q14.3 which is associated with
suppressing tumor cell viability in cancers [24].
Furthermore, we observed a significant decrease in
both chemotherapeutic and immunotherapeutic responses
of DLEU1 KD cells as compared to WT with CTX and
RTX, respectively, suggests that a DLEU1 loss may in
part be a potential mechanism for therapeutic resistance.
We then established in vivo xenograft NSG mouse models
with DLEU1 knockdown and overexpressing Raji cells
and investigated the sensitivity of these xenograft tumors
to the treatment of RTX and/or CTX. More importantly,
the deletion of DLEU1 results in significant enhancement
of tumor progression and shortened survival in RTX and
CTX treated DLEU1 KD cells xenografted mice compared
to WT cell injected mice. In contrast, GFP-DLEU1
BL xenografted mice treated with RTX and/or CTX
exhibited a significant survival advantage over control BL
xenografted mice. These data in part suggest that DLEU1
level is associated with chemoimmunotherapy resistance.
The use of a TALENs method provided an
opportunity to investigate the loss of function of a specific
gene [26–29]. While this study sheds some light on at
least one mechanism of chemoimmunotherapy resistance
in BL, it will be important to investigate the role of
other gene products found in the 13q14.3 region such
as microRNA clusters, miR-15a/miR-16-1 [24, 30], and
long non-coding RNA (lncRNA) gene, DLEU2 [24], and
RFP2 and/or KCNRG [31]. DLEU1 may perhaps work
in tandem with miR-15a/miR-16-1, DLEU2 and/or RFP2
to create an additive or synergistic tumor suppressive or
oncogenic effect. We plan to investigate in future studies
the individual and combined roles of miR-15a, miR-16-1,
DLEU2 and/or RFP2 by molecular excision via TALENs
in BL lymphomagenesis and their importance in regulating
BL programmed cell death.
Interestingly, DLEU1 has been considered as a
lncRNA gene [16, 17, 24]. However, DLEU1 was defined
as putative functional protein coding gene that encodes
a 78 amino acids based on Ensemle database [32] and
the universal protein resource (UniProt) [33, 34]. It has
recently been implicated that predicted open reading
frame in lncRNA can be translated to functional peptides
[35, 36]. A human protein-protein interaction study
showed an interaction between DLEU1 and TUBB2C,
www.impactjournals.com/oncotarget

TUBB2C and Bruton’s tyrosine kinase (BTK) [37, 38],
suggesting that DLEU1 may interact with BTK. BTK
is a regulator of normal B-cell development and is
activated upon B-cell receptor (BCR) stimulation [39]. In
addition, BTK has recently become an important target
in hematological malignancies, with the development of
various targeted therapies specifically targeted to inhibit
BCR signaling [40, 41]. Specifically, a BTK-targeting
molecule, ibrutinib has been approved by FDA for
treatment of CLL and MCL patients who have failed prior
therapy and is currently under pre-clinical investigation
for treatment of BL [42]. We aim to further investigate
the potential connection between DLEU1 and the BCR
signaling pathways, and the role of this relationship in BL.
In summary, our results suggest that the deletion
of DLEU1 at 13q14.3 in BL may in part result in
chemoimmunotherapy resistance in BL. Furthermore,
there is also the implication for pretreatment screening
for the presence of the 13q14.3 deletion in children and
adolescent BL and the potential investigation of alternative
therapeutic strategies. In future studies, we will address
which therapies may perhaps re-sensitize BL cells
lacking the 13q14.3 region to improve therapy induced
programmed cell death.

MATERIALS AND METHODS
Ethics statement
Investigation has been conducted in accordance with
the ethical standards and according to the Declaration of
Helsinki and according to national and international
guidelines and has been approved by the Institutional
Animal Care and Use Committee at New York Medical
College.

Engineering of transcription activator-like
effector nucleases (TALENs) targeting DLEU1
Potential TALENs target sites of DLEU1 were
identified using web-based ZiFiT Targeter software
(http://zifit.partners.org/). The BLAST analysis and
Repeat Masker Web server (www.repeatmasker.org)
were utilized for uniqueness of targeted sequences.
The designed DLEU1 TALEN pairs were constructed
based on Restriction Enzyme And Ligation (REAL)
assembly methods using the Joung Lab REAL Assembly
TALENS kit from Addgene [43]. TALENs were designed
to target the DLEU1 transcription start and stop site
on chromosome 13q14.3. To examine the validity of
constructed TALENs pairs in mammalian cells, plasmids
expressing each TALENs pair were transfected into
Human embryonic kidney (HEK)293 cells and genomic
DNA was extracted 24 hours post-transfection. Disrupted
target sequences caused by non-homologous end joining
(NHEJ) were confirmed by surveyor mutation detection
27848
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assay (Supplementary Figure 1) and sequencing analysis
(data not shown).

qScript™ cDNA Synthesis Kit (Quantas). qRT-PCR was
performed on the CFX96 Real-time system (Bio-rad) using
SsoFast™ EvaGreen® Supermix (Bio-rad). Primers used in
qRT-PCR are provided in Supplementary Table 2. Relative
quantification (ddCt) of mRNA expression of genes was
determined by normalizing to the housekeeping gene,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

Cell culture and transfection
HEK293 and Raji human BL cells were obtained
from ATCC (Manassas, VA) and maintained as previously
described [44, 45]. These cell lines were authenticated
by ATCC, and were provided us within 6 months before
the use of cells, and cells were passaged for fewer than
8 weeks of resuscitation in our laboratory. Plasmid
constructs were transfected into HEK293 and Raji cells
using Lipofectamine® reagent (Invitrogen) and Amaxa
Nucleofector™ Kit V (Lonza), respectively according to
the manufacturer instructions.

Western blotting analysis
Western blot analysis was performed as we have
previously described [44]. Band intensities on SDSPAGE gel were measured using ImageJ software program.
Antibodies specific for GAPDH, phospho-Akt and Akt,
phospho-IκBα and IκBα and GFP were purchased from
Cell Signaling Technology and an antibody specific for
DLEU1 was provided by ProteinTech. Antibodies specific
for anti-apoptotic genes, Bcl-2, Bcl-xL, and Mcl-1 and
pro-apoptotic proteins, Bad and Bax were purchased from
Cell Signaling Technology.

Surveyor nuclease assay
Genomic DNA was extracted from cells
24–48 hours post-transfection using a genomic DNA
extraction kit (Promega). The measurement of NHEJ mediated mutation was performed using the Surveyor
endonuclease assay kit (Transgenomic, Inc.) according to
the manufacturer’s instructions. The PCR primers used
are as follows: F2, 5′-TCTTGCTTTCCCGACATTT
TTACG-3′, F4, 5′-CTAGAAGAGCCAACCAACAG-3′,
and R1, 5′-AGTTGTTCCGAGGCTTAAGTGC GA-3′.

Cell proliferation assay
Prior to cell proliferation measurements, cells were
treated without or with various doses of RTX (0 – 100 ug/
ml), CTX (0 – 10 mM) alone and in combination. Cells
(1 × 104) were plated into 48 well plates and then counted every
24 hrs as previously described [44]. Cell growth was
determined using the non-radioactive CellTiter 96® Aqueous
One solution cell proliferation assay (MTS) (Promega) and
measured by a Multiabel Counter (Perkin Elmer) at OD490.

Generation of TALENs mediated DLEU1
knockdown cell line
Cells were transfected with TALEN expression
plasmids and genomic DNA was extracted at 48 hours
post-transfection followed by Surveyor nuclease assay as
above. Raji cells with DLEU1 gene modification identified
by NHEJ were seeded into 96 well plates to isolate a
single clone. Individual colonies were picked, expanded
and re-genotyped as described above.

Caspase 3/7 assay
Caspase 3/7 activity was directly measured at 48 and
72 hours after treatment using Caspase-Glo 3/7 Activity
kit (Promega) according to the manufacturer’s protocol.
Relative light intensity was measured in each well using
Clarity Luminescence Microplate Reader (BioTek).

Establishment of BL cell line stably
overexpressing DLEU1

Antibodies and reagents
A chimeric human and mouse anti-CD20 type I
mAb, Rituximab (RTX), was purchased from Genentech
Inc. and CTX was purchased from Sigma Aldrich and
dissolved as a stock solution in PBS.

The DLEU1 overexpression construct (GFPDLEU1) was generated by cloning the full length DLEU1
cDNA into pEGFP-N3 vector. GFP-DLEU1 was then
transfected into 293T or Raji cells. Cells were selected
under G418 (500 ug/ml) for stable clones and expression
of GFP-DLEU1 was confirmed by qRT-PCR and Western
blotting analyses.

Gene expression profiling
Gene expression profiling experiments were
performed using Affymetrix Human Genome 133 Plus
2.0 arrays at the Rockefeller University Genomics Facility.
Two hundred nanograms of total RNA were biotin-labeled
using Ambion MessageAmp™ Premier RNA Amplification
Kit (Life Technologies). The fragmented aRNA was
hybridized to the array as described in the Affymetrix

Quantitative reverse-transcriptase PCR (qRTPCR)
Total RNA was prepared using TRIzol reagent
(Invitrogen) according to the manufacturer’s instruction
and 1 ug of RNA was used for cDNA synthesis using
www.impactjournals.com/oncotarget
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Technical Analysis Manual (Affymetrix). Gene Chips
were stained with streptavidin-phycoerythrin, and then
scanned with the Affymetrix GeneChip Scanner 3000 7G.
Data has been deposited in the NCBI’s Gene Expression
Omnibus data base (accession number GSE65674).

the Kaplan-Meier method and differences evaluated by
log-rank test using the Prism Version 6.0 software.
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Microarray data processing and analysis
Signal intensity was processed using MAS5
algorithm. The Probe sets that were not tagged as present
in any samples according to the presence-absence-call
and control probe sets were discarded. Among 21,437
surviving probe sets, we identified probe sets whose signal
ratio between test group average and control group average
exceeded two-fold as DEG [46] and retained for further
analyses. We used DAVID (version 6.7) to investigate the
biological processes and pathways implicated by DEG
[47]. Specifically, we employed the functional annotation
clustering utility that clusters functionally related terms
linked to DEG. We interrogated over-expressed and underexpressed probe sets separately.
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1 day before cell transplantation. DLEU1-KD and mock
control (WT), or GFP-DLEU1 and mock control (GFP)
were transfected with a firefly luciferase expression
plasmid (ffluc-zeo, kindly provided by Laurence Cooper
MD, PhD) into Raji cells followed by zeocin selection
for stable clones. These selected cells (1 × 106) were then
subcutaneously injected into four- to six-week-old female
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice from
Jackson laboratory. After verification of tumor burden by
bioluminescence imaging using the Xenogen IVIS-200
(Caliper Life Sciences), mice were treated with either PBS
control (n = 5 per group), or RTX (30 mg/kg, n = 12 per
group), or CTX (25 mg/kg, n = 12 per group) or RTX
together with CTX (n = 12 per group) by intraperitoneal
(i.p) injection at 7 day intervals as we have previously
described [48]. Tumor progression was monitored at day
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